Peptide hormone markers in screening for endocrine tumors in multiple endocrine adenomatosis type I.
In three families with the multiple endocrine adenomatosis type I (MEA I) trait, 51 members were investigated by measurement of circulating peptide hormones as tumor markers. Twenty-five of 51 members (49 percent) were considered to be affected by MEA I disorders. The incidence rose with age (75 percent in generation II). Both sexes were affected equally. Hyperparathyroidism was present in 20 of 25 affected members (80 percent), and pituitary tumors (prolactinomas) were found in four of 25 (16 percent). Endocrine pancreatic tumors were found in nine of 25 affected members (36 percent), but when "probable" tumors (seven) are included the frequency rises to 72 percent. Hyperparathyroidism was found in all except one member with proved lesions in other organs. Among patients with proved and possible endocrine pancreatic tumors, elevated serum levels of gastrin and pancreatic polypeptide were frequently found, 78 percent and 67 percent, respectively, and we suggest that serum gastrin and pancreatic polypeptide levels are the most useful screening markers at present for pancreatic lesions in MEA I.
D000236:Adenoma / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D005260:Female; D005755:Gastrins / Q000097:blood; D006801:Humans; D006961:Hyperparathyroidism / Q000235:genetics; D007340:Insulinoma / Q000601:surgery; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000097:blood; D010191:Pancreatic Polypeptide / Q000097:blood; D010282:Parathyroid Neoplasms / Q000601:surgery; D010375:Pedigree; D014660:Vasoactive Intestinal Peptide / Q000097:blood; D015043:Zollinger-Ellison Syndrome / Q000097:blood
D005755:Gastrins; D014660:Vasoactive Intestinal Peptide; D010191:Pancreatic Polypeptide